InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,705.97
(
-0.13%
)
US TECH 100
19,288.80
(
-0.24%
)
Dow Jones
42,117.57
(
0.22%
)
Brent Oil
74.23
(
-0.13%
)
Bitcoin
62,680.88
(
-0.43%
)
Post# of 19856
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

gfp927z

Send PM Follow Ignore
Followers 87
Posts 33386
Boards Moderated 87
Alias Born 03/22/2005

gfp927z

Re: None

Wednesday, 07/01/2020 9:11:07 AM

Wednesday, July 01, 2020 9:11:07 AM

Post# of 19856
One downside with Humanigen is they appear to be running on fumes. They filed a shelf registration recently, so will probably be doing a financing soon.

The chart looks a lot like CYDY's, having risen from .30 cents to the current $5 area. The market cap is still only $620 mil, compared to CYDY's $3 bil.

HGEN's drug sounds interesting, and the near term catalyst should be the upcoming interim analysis of the Phase 3 Covid trial (coming soon). This analysis will apparently be on 1/2 of the total patients, so approx 119 patients vrs CYDY's interim analysis on 50 patients in the severe trial.

So another contender in the 'Covid Casino'..


















Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up